Cleveland Clinic Cardiovascular Update 2025
$79.99
New Year Sale!
- 30% OFF for orders above $299! Use code: BEST30
Description
Cleveland Clinic
Cardiovascular Update
| Session 1: Prevention and Management of Cardiovascular Risk, Part 1 | |
| Tools in CVD Prevention and Risk Management: To Test or Not to Test? Lp(a),apoB, Non HDL-C | Dennis Bruemmer, MD, PhD |
| Statin Initiation for Primary Prevention Among Statin Naïve Adults and Reasons for Nonadherence | Vikas Sunder, MD |
| When Statins Are Not Enough – Non-statin Lipid Lowering Therapies to Manage Residual Risk | Ashish Sarraju, MD |
| Managing Anti-Hyperglycemic and CV Risk Reduction Agents in Patients With Diabetes: SGLT2i or GLP1RA or Both? | Dennis Bruemmer, MD, PhD |
| Weight Loss Pharmacotherapy: Utilizing Current Therapies and Exploring the Next Generation of Weight Loss Medications | Steve Nissen, MD |
| Keto, Low Carb, Plant Based, IF: Controversies in the Evidence for the “Best “Diet: What is the Evidence and How to Apply in Clinical Practice | Julia Zumpano, RD, LD |
| Old and Evolving Strategies for Treatment-Resistant Hypertension | Luke Laffin, MD |
| Social Determinants of Health and Cardiovascular Disease: Current State and Future Directions | Lee Kirksey, MD |
| Panel Discussion/Q&A | Session Faculty |
| Session 2: Prevention and Management of Cardiovascular Risk, Part 2 | |
| Hormone Therapy and Heart Health: Debunking Myths, Embracing Evidence | Luke Laffin, MD |
| The Intersection of Cardiovascular Disease and Chronic Kidney Disease: Strategies for Reducing Cardiovascular Risk | Crystal Gadegbeku, MD |
| Who Should Get a CAC? How Often? How to Use the Results to Assess Risk? | Milind Desai, MD |
| Management of CV Issues in the Elderly: Geriatric Cardiology | Ardeshir Hashmi, MD |
| Population Health Management: Interventions to Control Cardiovascular Disease Risk Factors: Current Status | LeRoi Hicks, MD |
| Panel Discussion/Q&A | Session Faculty |
| Session 3: Special Populations | |
| Cardiac Disease Remains the Leading Cause of Mortality in Women: What are we Doing to Address This? | Vikas Sunder, MD |
| Cardiovascular Disease and Pregnancy: Optimizing Maternal and Fetal Health | Deirdre Mattina, MD |
| Competitive Sports Participation in Athletes with Heart Disease: Evaluation and Management | Tamanna Singh, MD |
| Cardio-oncology: Optimizing the Balance Between Cancer Outcomes and Cardiac Success | Patrick Collier, MD, PhD |
| Panel Discussion/Q&A | Session Faculty |
| Session 4: Essentials of Cardiovascular Disease | |
| Role of Advanced Imaging for Ischemic Heart Disease: CT, CMR, Nuclear and Advanced Echocardiography | Saberio Lo Presti Vega, MD |
| Creating a Pathway for the Management of Stable Angina in Your Clinic: Structured Risk Assessment and Clinical Decision Making | Ben Alencherry, MD |
| ANOCA, INOCA, MINOCA: What Does It All Mean? Diagnostic Testing and Therapeutic Management | Khalid Ziada, MD |
| How Do I Manage my Post MI Patient (Including DAPT Guidelines/Duration/CardiacRehab) | Venu Menon, MD |
| Cardiac Rehab: Why it is Critical and How Can We Improve Access and Compliance? | Erik Van Iterson, PhD, MS |
| Peripheral Artery Disease: Assessment and Clinical Decision Making | Lee Kirksey, MD |
| Panel Discussion/Q&A | Session Faculty |
| Session 5: Structural Heart Disease | |
| Aortic Stenosis: Diagnosis and Management in the Modern Era | Samir Kapadia, MD |
| MR: How to Diagnose and Manage Mitral Valve Disease: When to Refer? What are the Options | L. Leonardo Rodriguez, MD |
| What to Know About the Natural History of Tricuspid Regurgitation: Current and Future Management Strategies | Amar Krishnaswamy, MD |
| Bicuspid and Aneurysm-Associated Aortic Valve Disease: Timing of Intervention and the Role of Family Screening | Milind Desai, MD |
| Guidelines for Anticoagulation Following Structural Heart Therapies | Grant Reed, MD, MSc |
| Hypertrophic Cardiomyopathy: Co-management in the Era of Emerging Precision Therapies | Milind Desai, MD |
| Panel Discussion/Q&A | Session Faculty |
| Session 6: Heart Failure | |
| Heart Failure Stages, Phenotypes and Diagnosis and How to Screen for HF in the Primary Care Setting | Randall Starling, MD |
| HFrEF: Essentials of Guideline Directed Medical Therapy Initiation and Titration | Amanda Vest, MBBS |
| Managing Comorbidities in HF: Frailty, Anemia, Sleep Apnea, AF, Obesity | Karlee Hoffman, DO |
| Essentials of Diagnosis and Management for HFpEF | Sanjeeb Bhattacharya, MD |
| Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Mazen Hanna, MD |
| Strategies to Enhance GDMT Implementation and Adherence | M. Trejeeve Martyn, MD |
| Managing Long Term LVADs and Transplant Recipients in the Community Setting | Ike Okwuosa, MD |
| The Importance of Collaboration Between EP and HF: CRT and Novel Pacing | Niraj Varma, MD, PhD |
| Panel Discussion/Q&A | Session Faculty |
| Session 7: Heart Rhythm | |
| Diagnosis and Management of New-Onset Atrial Fibrillation | Mohamed Kanj, MD |
| AF and Left Atrial Appendage Closure: Current and Future Directions | Mohamed Kanj, MD |
| What I Need to Know to Evaluate and Manage the Patient With PVCs and SVT | Pasquale Santangeli, MD, PhD |
| Evaluation and Management of Syncope in the Young Adult | Kenneth Mayuga, MD |
| Follow-Up of Pacemakers and ICDs For the Non-Electrophysiologist | Kevin F. Kwaku, MD, PhD |
| Wearables for Arrhythmia Care: Current Challenges and Future Prospects | Niraj Varma, MD, PhD |
| Panel Discussion/Q&A | Session Faculty |
End
